Janux Therapeutics (NASDAQ:JANX) CEO David Alan Campbell Sells 8,072 Shares of Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 8,072 shares of the business’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $13.73, for a total value of $110,828.56. Following the completion of the transaction, the chief executive officer directly owned 284,982 shares in the company, valued at $3,912,802.86. This represents a 2.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Janux Therapeutics Trading Down 1.1%

NASDAQ JANX traded down $0.15 during trading hours on Friday, hitting $13.65. 1,533,974 shares of the company’s stock were exchanged, compared to its average volume of 2,182,684. The firm has a market cap of $821.05 million, a price-to-earnings ratio of -8.13 and a beta of 2.88. The stock has a 50-day simple moving average of $22.51 and a 200 day simple moving average of $23.74. Janux Therapeutics, Inc. has a 1-year low of $13.52 and a 1-year high of $61.59.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.21. The business had revenue of $10.00 million for the quarter, compared to the consensus estimate of $3.07 million. On average, sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Institutional Trading of Janux Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Osaic Holdings Inc. grew its holdings in Janux Therapeutics by 704.6% during the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after buying an additional 3,037 shares in the last quarter. Virtus Investment Advisers LLC grew its stake in shares of Janux Therapeutics by 37.9% in the 2nd quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock worth $85,000 after acquiring an additional 1,011 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Janux Therapeutics by 175.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock worth $91,000 after acquiring an additional 2,502 shares in the last quarter. Ameritas Investment Partners Inc. raised its holdings in shares of Janux Therapeutics by 25.6% in the second quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock valued at $93,000 after purchasing an additional 820 shares during the last quarter. Finally, Winthrop Capital Management LLC bought a new position in shares of Janux Therapeutics during the third quarter valued at about $106,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Bank of America decreased their price target on shares of Janux Therapeutics from $58.00 to $49.00 and set a “buy” rating for the company in a research note on Tuesday, December 2nd. Stifel Nicolaus dropped their price target on Janux Therapeutics from $46.00 to $38.00 and set a “buy” rating on the stock in a research note on Tuesday, December 2nd. Wall Street Zen raised Janux Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Wolfe Research assumed coverage on Janux Therapeutics in a report on Tuesday, November 18th. They set a “peer perform” rating for the company. Finally, Wedbush reiterated an “outperform” rating and issued a $45.00 target price (down from $76.00) on shares of Janux Therapeutics in a report on Tuesday, December 2nd. Twelve analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $61.08.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.